The Clinical Trials Arena spoke to industry experts about what challenges the sector can expect to face in 2025.

Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for ulcerative ...

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

JP Morgan attendees were told of Jazz Pharmaceuticals' plans to expand indications for two oncology drugs: zanidatamab and ...

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

The Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics' GOBLET trial ...